Skip to main content
SpringerLink
Log in

Effect of VSL#3 Probiotic in a Patient with Glycogen Storage Disease Type Ia and Irritable Bowel Disease-like Disease

  • Published:
Probiotics and Antimicrobial Proteins Aims and scope Submit manuscript

Abstract

Gut Inflammatory bowel disease (IBD) is a group of chronic gastrointestinal disorders characterised by relapsing and remitting inflammation of the gastrointestinal tract. The two most common types of IBDs are ulcerative colitis and Crohn’s disease. Patients with glycogen storage disease (GSD) type Ia present with gastrointestinal symptoms such as recurrent abdominal pain, bloating and changes in stool form or frequency, which is clinically difficult to distinguish from IBD. We report the case of a 36-year-old man with GSD type Ia and IBD-like disease. A commercial probiotic (VSL#3®) was chosen as a nutritional supplement treatment because of its high content of microbial species and strains. Three different tests were performed: normal-dose, no-dose and half-dose tests. The study periods for the normal-dose, no-dose and half-dose tests were 4 weeks from the treatment initiation, 72 h from the end of the previous period and 4 weeks to 6 months after the end of the 72-h period, respectively. When the probiotic treatment was stopped, he experienced several symptoms similar to those before the start of the treatment. The intestinal symptoms were less severe with the half-dose nutritional supplement treatment than with no treatment. Probiotics may reduce the number of irritable gut episodes and improve the patient’s well-being and overall quality of life. More studies are needed to determine whether the improvement in more severe cases of GSD is due mainly to changes in the composition of the gut microbiota, as in this patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Chen YT (2001) Glycogen storage diseases. In: Scriver C, Beaudet A, Sly W, Valle D (eds) The metabolic & molecular bases of inherited disease. McGraw-Hill, New York, pp 1521–1551

    Google Scholar 

  2. Fine RN, Kogut MD, Donnell GN (1969) Intestinal absorption in type I glycogen storage disease. J Pediatr 75(4):632–635. https://doi.org/10.1016/S0022-3476(69)80459-2

    Article  CAS  PubMed  Google Scholar 

  3. Lawrence NT, Chengsupanimit T, Brown LM, Derks TGJ, Smit GPA, Weinstein DA (2017) Inflammatory bowel disease in glycogen storage disease type Ia. J Pediatr Gastroenterol Nutr 64(2):e52–e54. https://doi.org/10.1097/MPG.0000000000000592

    Article  PubMed  Google Scholar 

  4. Lawrence NT, Chengsupanimit T, Brown LM, Weinstein DA (2015) High incidence of serologic markers of inflammatory bowel disease in asymptomatic patients with glycogen storage disease type Ia. JIMD Rep 24:123–128. https://doi.org/10.1007/8904_2015_452

    Article  PubMed  PubMed Central  Google Scholar 

  5. Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448(7152):427–434. https://doi.org/10.1038/nature06005

    Article  CAS  PubMed  Google Scholar 

  6. Laparra JM, Sanz Y (2010) Interactions of gut microbiota with functional food components and nutraceuticals. Pharmacol Res 61(3):219–225. https://doi.org/10.1016/j.phrs.2009.11.001

    Article  CAS  PubMed  Google Scholar 

  7. Aureli P, Capurso L, Castellazzi AM, Clerici M, Giovannini M, Morelli L, Poli A, Pregliasco F, Salvini F, Zuccotti GV (2011) Probiotics and health: an evidence-based review. Pharmacol Res 63(5):366–376. https://doi.org/10.1016/j.phrs.2011.02.006

    Article  CAS  PubMed  Google Scholar 

  8. Phillips ML (2009) Gut reaction: environmental effects on the human microbiota. Environ Health Perspect 117(5):A198–A205. https://doi.org/10.1289/ehp.117-a198

    Article  PubMed  PubMed Central  Google Scholar 

  9. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, MetaHIT Consortium, Bork P, Ehrlich SD, Wang J (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464(7285):59–65. https://doi.org/10.1038/nature08821

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Tappenden KA, Deutsch AS (2007) The physiological relevance of the intestinal microbiota—contributions to human health. J Am Coll Nutr 26(6):679S–683S

    Article  PubMed  Google Scholar 

  11. Resta SC (2009) Effects of probiotics and commensals on intestinal epithelial physiology: implications for nutrient handling. J Physiol 587(Pt17):4169–4174. https://doi.org/10.1113/jphysiol.2009.176370

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Brahe LK, Chatelier EL, Prifti E, Brahe LK, Chatelier EL, Prifti E, Pons N, Kennedy S, Hansen T, Pedersen O, Astrup A, Ehrlich SD, Larsen LH (2015) Specific gut microbiota features and metabolic markers in postmenopausal women with obesity. Nutr Diab 5(6):e159. https://doi.org/10.1038/nutd.2015.9

    Article  CAS  Google Scholar 

  13. Larsen N, Vogensen FK, van den Berg FWJ, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH, Jakobsen M (2010) Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 5(2):e9085. https://doi.org/10.1371/journal.pone.0009085

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Whelan K, Quigley EM (2013) Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol 29(2):184–189. https://doi.org/10.1097/MOG.0b013e32835d7bba

    Article  PubMed  Google Scholar 

  15. Scaldaferri F, Gerardi V, Lopetuso LR, Zompo FD, Mangiola F, Boškoski I, Bruno G, Petito V, Laterza L, Cammarota G, Gaetani E, Sgambato A, Gasbarrini A (2013) Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. Biomed Res Int 2013:435268–435269. https://doi.org/10.1155/2013/435268

    Article  PubMed  PubMed Central  Google Scholar 

  16. Ritchie ML, Romanuk TN (2012) A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One 7(4):e34938. https://doi.org/10.1371/journal.pone.0034938

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Champagne CP, Ross RP, Saarela M, Hansen KF, Charalampopoulos D (2011) Recommendations for the viability assessment of probiotics as concentrated cultures and in food matrices. Int J Food Microbiol 149(3):185–193. https://doi.org/10.1016/j.ijfoodmicro.2011.07.005

    Article  PubMed  Google Scholar 

  18. Abayasekara LM, Perera J, Chandrasekharan V, Gnanam VS, Udunuwara NA, Liyanage DS, Bulathsinhala NE, Adikary S, Aluthmuhandiram JVS, Thanaseelan CS, Tharmakulasingam DP, Karunakaran T, Ilango J (2017) Detection of bacterial pathogens from clinical specimens using conventional microbial culture and 16S metagenomics: a comparative study. BMC Infect Dis 17(1):631. https://doi.org/10.1186/s12879-017-2727-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Argollo M, Fiorino G, Hindryckx P, Peyrin-Biroulet L, Danese S (2017) Novel therapeutic targets for inflammatory bowel disease. J Autoimmun 85:103–116. https://doi.org/10.1016/j.jaut.2017.07.004

    Article  CAS  PubMed  Google Scholar 

  20. Kim YA, Keogh JB, Clifton PM (2017) The anti-diabetic effects of probiotics include reducing pro-inflammatory cytokines via a NF-κB pathway, reduced intestinal permeability, and lowered oxidative stress. Nutr Res Rev 17:1–17. https://doi.org/10.1017/S095442241700018X

    Article  CAS  Google Scholar 

  21. Hegazy SK, El-Bedewy MM (2010) Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis. World J Gastroenterol 16(33):4145–4151. https://doi.org/10.3748/wjg.v16.i33.4145

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Rasmussen HE, Hamaker BR (2017) Prebiotics and inflammatory bowel disease. Gastroenterol Clin N Am 46(4):783–795. https://doi.org/10.1016/j.gtc.2017.08.004

    Article  Google Scholar 

  23. Buss C, Valle-Tovo C, Miozzo S, Alves de Mattos A (2014) Probiotics and synbiotics mayimprove liver aminotransferases levels in non-alcoholic fatty liver disease patients. Ann Hepatol 13(5):482–488

    Article  PubMed  Google Scholar 

  24. Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, Bazhukova TA, Soloviev AG, Barve SS, McClain CJ, Cave M (2008) Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 42(8):675–682. https://doi.org/10.1016/j.alcohol.2008.08.006

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Khalesi S, Johnson DW, Campbell K, Williams S, Fenning A, Saluja S, Irwin C (2017) Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis. Eur J Nutr. https://doi.org/10.1007/s00394-017-1568-y

  26. Ministro P, Martins D (2017) Fecal biomarkers in inflammatory bowel disease: how, when and why? Expert Rev Gastroenterol Hepatol 11(4):317–328. https://doi.org/10.1080/17474124.2017.129212

    Article  CAS  PubMed  Google Scholar 

  27. Conroy S, Hale MF, Cross SS, Swallow K, Sidhu RH, Sargur R, Lobo AJ (2017) Unrestricted faecal calprotectin testing performs poorly in the diagnosis of inflammatory bowel disease in patients in primary care. J Clin Pathol. https://doi.org/10.1136/jclinpath-2017-204506

Download references

Acknowledgements

We thank the staff of the Endocrinology and Nutrition consultation of the University of Santiago de Compostela Hospital Complex for their help in conducting the anthropometric measures.

Funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Biochemistry, Genetics and Immunology Department, University of Vigo, Vigo, Spain

    Miguel Carnero-Gregorio

  2. Efficiency, Quality and Costs in Health Services Research Group (EFISALUD), Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, Vigo, Spain

    Miguel Carnero-Gregorio, Alberto Molares-Vila, Alberte Corbalán-Rivas & Carmen Rodríguez-Cerdeira

  3. Department of Food and Analytic Chemistry, University of Vigo, Vigo, Spain

    Alberto Molares-Vila

  4. Spanish Glycogen Storage Disease Association (AEEG), Donosti, Spain

    Alberte Corbalán-Rivas

  5. Statistics and Operative Research Department, University of Vigo, Vigo, Spain

    Carlos Villaverde-Taboada

  6. Dermatology Department, University Hospital Complex of Vigo (CHUVI), Hospital do Meixoiero, C/ Meixoeiro S/N, Vigo, Spain

    Carmen Rodríguez-Cerdeira

Authors
  1. Miguel Carnero-Gregorio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto Molares-Vila
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alberte Corbalán-Rivas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carlos Villaverde-Taboada
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carmen Rodríguez-Cerdeira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carmen Rodríguez-Cerdeira.

Ethics declarations

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Competing Interest

The authors declare that there are no competing interests regarding the publication of this paper.

Ethical Responsibilities

Right to privacy and informed consent. The authors have obtained informed consent of the patients and/or subjects referred to in the manuscript.

Electronic Supplementary Material

ESM 1

(DOCX 19 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carnero-Gregorio, M., Molares-Vila, A., Corbalán-Rivas, A. et al. Effect of VSL#3 Probiotic in a Patient with Glycogen Storage Disease Type Ia and Irritable Bowel Disease-like Disease. Probiotics & Antimicro. Prot. 11, 143–149 (2019). https://doi.org/10.1007/s12602-017-9372-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12602-017-9372-9

Keywords

Search

Navigation